amfAR report examines controversial pricing of hepatitis C treatment
NEW YORK – Despite important price reductions for some low- and middle-income countries, the exorbitant drug pricing of breakthrough treatments for hepatitis C (HCV) infection will inevitably limit access to the drugs, leading to unnecessary loss of life, according to a new report from amfAR, The Foundation for AIDS Research. While the new drugs have…
